National Cancer Institute (NCI): Pancreatic Neoplasms trials
The registry lists 110 Pancreatic Neoplasms studies with National Cancer Institute (NCI) as lead sponsor. 14 are open to participants now and 37 have results posted.
Phase 1 56Phase 2 61Phase 3 1No phase 7(a study in two phases counts in both)
Studies
Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- LMB-9 Immunotoxin in Treating Patients With Advanced Solid TumorsCompletedNCT00019435Phase 1
- Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid TumorsCompletedNCT00019331Phase 2
- Vaccine Therapy and Biological Therapy in Treating Patients With Advanced CancerCompletedNCT00019084Phase 2
- Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung CancerCompletedNCT00019006Phase 1
- Immunotoxin Therapy in Treating Patients With Advanced CancerCompletedNCT00006981Phase 1
- Gemcitabine, Herceptin and Radiation to Treat Cancer of the PancreasCompletedNCT00005926Phase 2
- R115777 in Treating Patients Who Have Metastatic Pancreatic CancerCompletedNCT00005843Phase 2
- Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
- A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by RituximabCompletedNCT00001805Phase 2
- A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the PancreasCompletedNCT00001431Phase 1